期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

激素联合普萘洛尔治疗小儿血管瘤 被引量：4

下载PDF
导出
摘要 血管瘤为小婴儿常见疾病，部分患儿有巨大血管瘤合并血小板减少症，称为血管瘤伴血小板减少综合征（ kasabach-merritt syndrome, KMS ），于1940年由Ka—sabach和Merrtt报道，又称为K—M综合征。临床上比较少见，通常伴有全身出血倾向，病死率高，治疗难度大；气道多发性血管瘤临床少见，血管瘤在迅速增生期时可导致气道不完全梗阻，病情危重，需积极救治。
作者 王晓颖
机构地区 首都儿科研究所附属儿童医院新生儿科
出处 《中国医刊》 CAS 2011年第11期89-91,共3页 Chinese Journal of Medicine
关键词 巨大血管瘤 普萘洛尔 治疗 血小板减少综合征 小儿 激素 血小板减少症 多发性血管瘤
分类号 R725.4 [医药卫生—儿科]
  • 相关文献

参考文献7

  • 1Alvarez-Mendoza A, Lourdes TS, Ridaura-Sanz C, et al. Histoapathology of vascular lesions found in Kasabach-Merritt syndrome: review based on 13cases [ J ]. Podialr Dev Path,2000,3 (6) : 556 - 560.
  • 2Sarkar M, Mulliken JB, Kozakewich HP,et al. Thrombocytopenic coagulopathy( Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma [ J ]. Plast Reconstr Surg, 1997,100 ( 6 ) : 1377 - 1386.
  • 3Haisley-Royster C, Enjolras D, Frieden IJ, et al. Kasabach-Merritt phenomenon : a retrospective study of treatment with vincristine [ J ]. J Pediatf Hernatol Oneol,2002,24 (6) : 459 - 462.
  • 4Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Proprano1ol for severe hemangiomas of infancy[ J ]. N Engl J Med,2008,358 ( 24 ) : 2649 - 2651.
  • 5Leaute-Labrieze C, Taieb A. Efficacy of beta-blockers in infantile haemangiomas: The physiopathologicalsignificance and therapentic consequences[ J ]. Ann Dermatol Venerol, 2008,135 ( 12 ) : 860 - 862.
  • 6Siegfried EC, Keenan WJ, AI-Jureidini S. More on propranolol for haemangiomas of infancy [ J ]. N Engl J Med, 2008,359 ( 26 ) : 2846 - 2847.
  • 7秦中平,刘学键,李克雷,周琴,杨秀娟,郑家伟.小剂量普萘洛尔口服治疗婴儿血管瘤的近期疗效与安全性评价[J].中华医学杂志,2009,89(44):3130-3134. 被引量：122

二级参考文献15

  • 1Metry D. Update on hemangiomas of infancy. Curt Opin Pediatr, 2004, 16:373-377.
  • 2Bennett ML, Fleiseher Jr AB, Chamlin SL, et al. Oral eortieosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol, 2001, 137 : 1208-1213.
  • 3Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha 2a therapy for life threatening hemangiomas of infancy. N Engl J Med, 1992, 326 : 1456-1463.
  • 4Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function-and life-threatening infantile hemangioma. Arch Pediatr, 2004, 11:99-107.
  • 5Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med, 2008, 358:2649-2651.
  • 6Waner M, Suen JY. A classification of congenital vascular lesions//Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck. New York: Wiley-Liss, 1999 : 1-12.
  • 7Achauer BM, Chang C J, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg, 1997, 99 : 1301-1308.
  • 8Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med, 2008, 359:2846.
  • 9Buekmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas : ease report of novel treatment. Laryngoscope, 2009, 119:2051-2054.
  • 10Gottschling S, Schneider G, Meyer S, et al. Two infants with life- threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer, 2006, 46:239-224.

共引文献121

同被引文献40

  • 1王勇,刘文英,唐耘熳,俞松,彭强.瘤内注射曲安缩松、地塞米松治疗儿童血管瘤[J].中国医刊,2004,39(12):30-31. 被引量：3
  • 2黄和平,胡琼华.婴幼儿皮肤增殖性血管瘤的治疗进展[J].中华医学美学美容杂志,2005,11(1):61-62. 被引量：23
  • 3Leaute-Labreze C, de la Roque E D, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [ J ]. New England Journal of Medicine, 2008, 358(24) :2649-2651.
  • 4HChen. Kasabach-Merritt Syndrome. Altas of Genetic Diagnosis and Counseling[J/OL]. DOl 10 1007/978-1-4614-1037-9-139.
  • 5Rodriguez V, Lee A, Witman PM, et al. Kasabach-merritt pheno?menon: case series and retrospective review of the mayo clinic experience[J]. Pediatr Hematol Oncol, 2009, 31(7):522-526.
  • 6Saito M, Gunji Y, Kashii Y, et al. Refractory kaposiform hemangio?endothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report[J].J Pediatr Hematol Oncol, 2009, 31(3):194-197.
  • 7Hall GW. Kasabach-Merritt syndrome: pathogenesis and mangagement[J]. BrJ Haematol, 2001,112(4):851-862.
  • 8Peker E, Kirimi E, Tuncer 0, et al. Brachial plexus paralysis due to giant cavernous hemangioma with Kasabach-Merritt syndrome: successful management with interferon alpha[J]. Platelets, 2009, 20(8):603-605.
  • 9DeniseJ JH, Ingrid MB, RozemarijnJV, et al. Kaposiform Hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment[J].J Pediatr Hematol Oncol, 2011,33:eI71-eI73.
  • 10Haisley-Royster C, Enjolras 0, Frieden IJ, et al. . Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine[J].J Pediatr Hematol Oncol, 2002, 24(6):459-462.

二级引证文献14

中国医刊
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部